Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002702871 | SCV003564719 | pathogenic | Inborn genetic diseases | 2021-04-03 | criteria provided, single submitter | clinical testing | The c.309dupA (p.L104Tfs*20) alteration, located in exon 3 (coding exon 3) of the ALG8 gene, consists of a duplication of A at position 309, causing a translational frameshift with a predicted alternate stop codon after 20 amino acids. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. Based on the available evidence, this alteration is classified as pathogenic. |
Fulgent Genetics, |
RCV005011112 | SCV005631827 | likely pathogenic | ALG8 congenital disorder of glycosylation; Polycystic liver disease 3 with or without kidney cysts | 2024-06-07 | criteria provided, single submitter | clinical testing |